This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
In recent years, the adoption of advanced treatments in inflammatory bowel disease has evolved. Oral products have captured a significant share in ulcerative colitis, while Skyrizi, a 3rd generation biologic, has gained share in Crohn’s Disease. Despite these newer entrants, 1st generation biologics maintain significant patient share in both diseases.
At the 2026 JP Morgan Healthcare Conference, CRA hosted an expert panel session with health policy experts from the US, Germany, and the UK to discuss the...
The National Healthcare Security Administration (NHSA) engages clinical and negotiation experts to assess manufacturer submissions and establish a list of...
